معرفی
John A. Auchampach is a Professor in the Department of Pharmacology and Toxicology at the Medical College of Wisconsin (MCW). His research focuses on adenosine receptor signaling in cardiovascular diseases, particularly the roles of A2B and A3 adenosine receptors in myocardial infarction, cardiac fibrosis, and inflammation. He leads an NIH-funded laboratory investigating novel therapies for heart failure and ischemic injury, including Tip60 inhibition and allosteric modulators of adenosine receptors. Dr. Auchampach holds a PhD in Pharmacology and Toxicology from MCW (1992) and a BS in Pharmacy from South Dakota State University (1988).
Research highlights include developing genetic mouse models to study receptor deletion, echocardiography-based cardiac function analysis, and collaborations with Dr. John Lough on Tip60’s role in cardiomyocyte regeneration. The lab also works with chemists to design A3 receptor agonists and PAMs targeting inflammatory and neuropathic pain. Key findings include Tip60 inhibition reducing infarct injury and A3 receptor modulation mitigating ischemia/reperfusion damage.
Recent studies emphasize lipid-based drug optimization, species-specific receptor pharmacology, and G-protein/β-arrestin signaling preferences of macrocyclic agonists. Dr. Auchampach’s work bridges basic science and translational medicine, aiming to identify new therapeutic approaches for cardiovascular diseases.
